CA2748319A1 - Substituted quinazoline compounds of general formula (i) and uses thereof for treating disorders relating to tyrosine kinase dysregulation - Google Patents
Substituted quinazoline compounds of general formula (i) and uses thereof for treating disorders relating to tyrosine kinase dysregulation Download PDFInfo
- Publication number
- CA2748319A1 CA2748319A1 CA2748319A CA2748319A CA2748319A1 CA 2748319 A1 CA2748319 A1 CA 2748319A1 CA 2748319 A CA2748319 A CA 2748319A CA 2748319 A CA2748319 A CA 2748319A CA 2748319 A1 CA2748319 A1 CA 2748319A1
- Authority
- CA
- Canada
- Prior art keywords
- phenyl
- quinazolin
- ylamino
- chloro
- hydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 title abstract 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 title 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 title 1
- 230000008482 dysregulation Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 17
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 7
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 5
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- MZHYKEMGPNRRNY-OAQYLSRUSA-N 2-[4-[[6-(2-chloro-5-hydroxyphenyl)quinazolin-2-yl]amino]phenoxy]-1-[(3r)-3-(dimethylamino)pyrrolidin-1-yl]ethanone Chemical compound C1[C@H](N(C)C)CCN1C(=O)COC(C=C1)=CC=C1NC1=NC=C(C=C(C=C2)C=3C(=CC=C(O)C=3)Cl)C2=N1 MZHYKEMGPNRRNY-OAQYLSRUSA-N 0.000 claims 3
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- UWWLIQXOZPIZNJ-HHHXNRCGSA-N (2r)-1-[2-[3-[4-[[6-(2-chloro-5-hydroxyphenyl)-8-methylquinazolin-2-yl]amino]phenyl]-2-oxoimidazolidin-1-yl]ethyl]pyrrolidine-2-carboxylic acid Chemical compound N1=C2C(C)=CC(C=3C(=CC=C(O)C=3)Cl)=CC2=CN=C1NC(C=C1)=CC=C1N(C1=O)CCN1CCN1CCC[C@@H]1C(O)=O UWWLIQXOZPIZNJ-HHHXNRCGSA-N 0.000 claims 1
- SIACCBGVOWSQAC-AREMUKBSSA-N (2r)-1-[2-[4-[[6-(2,6-dimethylphenyl)quinazolin-2-yl]amino]phenoxy]ethyl]pyrrolidine-2-carboxylic acid Chemical compound CC1=CC=CC(C)=C1C1=CC=C(N=C(NC=2C=CC(OCCN3[C@H](CCC3)C(O)=O)=CC=2)N=C2)C2=C1 SIACCBGVOWSQAC-AREMUKBSSA-N 0.000 claims 1
- VTCLJEBTUYBWMX-RUZDIDTESA-N (2r)-1-[2-[4-[[6-(2-chloro-5-hydroxyphenyl)-8-methylquinazolin-2-yl]amino]phenoxy]ethyl]pyrrolidine-2-carboxylic acid Chemical compound N1=C2C(C)=CC(C=3C(=CC=C(O)C=3)Cl)=CC2=CN=C1NC(C=C1)=CC=C1OCCN1CCC[C@@H]1C(O)=O VTCLJEBTUYBWMX-RUZDIDTESA-N 0.000 claims 1
- MHCMBFVCAZAHNM-RUZDIDTESA-N 1-[(3r)-3-(dimethylamino)pyrrolidin-1-yl]-2-[4-[[6-(2,6-dimethylphenyl)quinazolin-2-yl]amino]phenoxy]ethanone Chemical compound C1[C@H](N(C)C)CCN1C(=O)COC(C=C1)=CC=C1NC1=NC=C(C=C(C=C2)C=3C(=CC=CC=3C)C)C2=N1 MHCMBFVCAZAHNM-RUZDIDTESA-N 0.000 claims 1
- DCUDFYSDQVJVAX-UHFFFAOYSA-N 1-[4-[4-[[6-(2,6-dimethylphenyl)quinazolin-2-yl]amino]phenyl]piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1NC1=NC=C(C=C(C=C2)C=3C(=CC=CC=3C)C)C2=N1 DCUDFYSDQVJVAX-UHFFFAOYSA-N 0.000 claims 1
- AMMREYAIIGJNRT-UHFFFAOYSA-N 1-[4-[4-[[6-(2-chloro-5-hydroxyphenyl)-8-methylquinazolin-2-yl]amino]phenyl]piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1NC1=NC=C(C=C(C=C2C)C=3C(=CC=C(O)C=3)Cl)C2=N1 AMMREYAIIGJNRT-UHFFFAOYSA-N 0.000 claims 1
- TYRDPAITJGOXCX-UHFFFAOYSA-N 1-[4-[[6-(2,6-dimethylphenyl)quinazolin-2-yl]amino]phenyl]-3-(2-pyrrolidin-1-ylethyl)imidazolidin-2-one Chemical compound CC1=CC=CC(C)=C1C1=CC=C(N=C(NC=2C=CC(=CC=2)N2C(N(CCN3CCCC3)CC2)=O)N=C2)C2=C1 TYRDPAITJGOXCX-UHFFFAOYSA-N 0.000 claims 1
- MCWXXILNYUKEIR-UHFFFAOYSA-N 1-[4-[[6-(2-chloro-5-hydroxyphenyl)-8-methylquinazolin-2-yl]amino]phenyl]-3-(2-pyrrolidin-1-ylethyl)imidazolidin-2-one Chemical compound N1=C2C(C)=CC(C=3C(=CC=C(O)C=3)Cl)=CC2=CN=C1NC(C=C1)=CC=C1N(C1=O)CCN1CCN1CCCC1 MCWXXILNYUKEIR-UHFFFAOYSA-N 0.000 claims 1
- SDNJFGWENJJGAI-AREMUKBSSA-N 1-[4-[[6-(2-chloro-5-hydroxyphenyl)-8-methylquinazolin-2-yl]amino]phenyl]-3-[2-[(3r)-3-(dimethylamino)pyrrolidin-1-yl]ethyl]imidazolidin-2-one Chemical compound C1[C@H](N(C)C)CCN1CCN1C(=O)N(C=2C=CC(NC=3N=C4C(C)=CC(=CC4=CN=3)C=3C(=CC=C(O)C=3)Cl)=CC=2)CC1 SDNJFGWENJJGAI-AREMUKBSSA-N 0.000 claims 1
- DYMFCCVAGSKVST-UHFFFAOYSA-N 1-[4-[[6-(2-chloro-5-hydroxyphenyl)quinazolin-2-yl]amino]phenyl]-3-(2-methoxyethyl)imidazolidin-2-one Chemical compound O=C1N(CCOC)CCN1C(C=C1)=CC=C1NC1=NC=C(C=C(C=C2)C=3C(=CC=C(O)C=3)Cl)C2=N1 DYMFCCVAGSKVST-UHFFFAOYSA-N 0.000 claims 1
- PWAQGFBFYOSQKM-UHFFFAOYSA-N 1-[4-[[6-(2-chloro-5-hydroxyphenyl)quinazolin-2-yl]amino]phenyl]-3-(2-pyrrolidin-1-ylethyl)imidazolidin-2-one Chemical compound OC1=CC=C(Cl)C(C=2C=C3C=NC(NC=4C=CC(=CC=4)N4C(N(CCN5CCCC5)CC4)=O)=NC3=CC=2)=C1 PWAQGFBFYOSQKM-UHFFFAOYSA-N 0.000 claims 1
- DKDSOJOOGBYVHM-JOCHJYFZSA-N 2-[4-[[6-(2-chloro-5-hydroxyphenyl)-8-methylquinazolin-2-yl]amino]phenoxy]-1-[(3r)-3-(dimethylamino)pyrrolidin-1-yl]ethanone Chemical compound C1[C@H](N(C)C)CCN1C(=O)COC(C=C1)=CC=C1NC1=NC=C(C=C(C=C2C)C=3C(=CC=C(O)C=3)Cl)C2=N1 DKDSOJOOGBYVHM-JOCHJYFZSA-N 0.000 claims 1
- BERSKKCARFLVRV-UHFFFAOYSA-N 3-[2-[4-[2-(azepan-1-yl)ethoxy]anilino]quinazolin-6-yl]-4-chlorophenol Chemical compound OC1=CC=C(Cl)C(C=2C=C3C=NC(NC=4C=CC(OCCN5CCCCCC5)=CC=4)=NC3=CC=2)=C1 BERSKKCARFLVRV-UHFFFAOYSA-N 0.000 claims 1
- SUSIZIGAKZXBKA-UHFFFAOYSA-N 4-chloro-3-[2-[3-(hydroxymethyl)anilino]-8-methylquinazolin-6-yl]phenol Chemical compound N1=C2C(C)=CC(C=3C(=CC=C(O)C=3)Cl)=CC2=CN=C1NC1=CC=CC(CO)=C1 SUSIZIGAKZXBKA-UHFFFAOYSA-N 0.000 claims 1
- LPMCVZGZXTUCIL-UHFFFAOYSA-N 4-chloro-3-[2-[4-(2-pyrrolidin-1-ylethoxy)anilino]quinazolin-6-yl]phenol Chemical compound OC1=CC=C(Cl)C(C=2C=C3C=NC(NC=4C=CC(OCCN5CCCC5)=CC=4)=NC3=CC=2)=C1 LPMCVZGZXTUCIL-UHFFFAOYSA-N 0.000 claims 1
- VGTYSWHJDXCEDB-UHFFFAOYSA-N 4-chloro-3-[8-methyl-2-[4-(2-pyrrolidin-1-ylethoxy)anilino]quinazolin-6-yl]phenol Chemical compound N1=C2C(C)=CC(C=3C(=CC=C(O)C=3)Cl)=CC2=CN=C1NC(C=C1)=CC=C1OCCN1CCCC1 VGTYSWHJDXCEDB-UHFFFAOYSA-N 0.000 claims 1
- XNURRHDXCWKBOG-UHFFFAOYSA-N 6-(2,6-dimethylphenyl)-n-(4-piperazin-1-ylphenyl)quinazolin-2-amine Chemical compound CC1=CC=CC(C)=C1C1=CC=C(N=C(NC=2C=CC(=CC=2)N2CCNCC2)N=C2)C2=C1 XNURRHDXCWKBOG-UHFFFAOYSA-N 0.000 claims 1
- XMEMWQHGCLIHOM-UHFFFAOYSA-N 6-(2,6-dimethylphenyl)-n-[4-(2-pyrrolidin-1-ylethoxy)phenyl]quinazolin-2-amine Chemical compound CC1=CC=CC(C)=C1C1=CC=C(N=C(NC=2C=CC(OCCN3CCCC3)=CC=2)N=C2)C2=C1 XMEMWQHGCLIHOM-UHFFFAOYSA-N 0.000 claims 1
- 101100295741 Gallus gallus COR4 gene Proteins 0.000 claims 1
- DPMRCMKQVYZSIO-UHFFFAOYSA-N [4-[4-[[6-(2,6-dimethylphenyl)quinazolin-2-yl]amino]phenyl]piperazin-1-yl]-pyridin-4-ylmethanone Chemical compound CC1=CC=CC(C)=C1C1=CC=C(N=C(NC=2C=CC(=CC=2)N2CCN(CC2)C(=O)C=2C=CN=CC=2)N=C2)C2=C1 DPMRCMKQVYZSIO-UHFFFAOYSA-N 0.000 claims 1
- MPNPFEPBTPBOAQ-UHFFFAOYSA-N [4-[4-[[6-(2-chloro-5-hydroxyphenyl)-8-methylquinazolin-2-yl]amino]phenyl]piperazin-1-yl]-pyridin-2-ylmethanone Chemical compound N1=C2C(C)=CC(C=3C(=CC=C(O)C=3)Cl)=CC2=CN=C1NC(C=C1)=CC=C1N(CC1)CCN1C(=O)C1=CC=CC=N1 MPNPFEPBTPBOAQ-UHFFFAOYSA-N 0.000 claims 1
- UKZPNRGUTKWSFX-UHFFFAOYSA-N [4-[4-[[6-(2-chloro-5-hydroxyphenyl)-8-methylquinazolin-2-yl]amino]phenyl]piperazin-1-yl]-pyridin-3-ylmethanone Chemical compound N1=C2C(C)=CC(C=3C(=CC=C(O)C=3)Cl)=CC2=CN=C1NC(C=C1)=CC=C1N(CC1)CCN1C(=O)C1=CC=CN=C1 UKZPNRGUTKWSFX-UHFFFAOYSA-N 0.000 claims 1
- MBVYOVSHWHBDPI-UHFFFAOYSA-N [4-[4-[[6-(2-chloro-5-hydroxyphenyl)-8-methylquinazolin-2-yl]amino]phenyl]piperazin-1-yl]-pyridin-4-ylmethanone Chemical compound N1=C2C(C)=CC(C=3C(=CC=C(O)C=3)Cl)=CC2=CN=C1NC(C=C1)=CC=C1N(CC1)CCN1C(=O)C1=CC=NC=C1 MBVYOVSHWHBDPI-UHFFFAOYSA-N 0.000 claims 1
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 150000002367 halogens Chemical group 0.000 claims 1
- YAMHXTCMCPHKLN-UHFFFAOYSA-N imidazolidin-2-one Chemical compound O=C1NCCN1 YAMHXTCMCPHKLN-UHFFFAOYSA-N 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 6
- 108091000080 Phosphotransferase Proteins 0.000 abstract 3
- 230000001404 mediated effect Effects 0.000 abstract 3
- 102000020233 phosphotransferase Human genes 0.000 abstract 3
- 206010012601 diabetes mellitus Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010038923 Retinopathy Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 229940043355 kinase inhibitor Drugs 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08360043 | 2008-12-29 | ||
| EP08360043.7 | 2008-12-29 | ||
| PCT/EP2009/067494 WO2010076238A1 (en) | 2008-12-29 | 2009-12-18 | Substituted quinazoline compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2748319A1 true CA2748319A1 (en) | 2010-07-08 |
Family
ID=41735344
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2748319A Abandoned CA2748319A1 (en) | 2008-12-29 | 2009-12-18 | Substituted quinazoline compounds of general formula (i) and uses thereof for treating disorders relating to tyrosine kinase dysregulation |
Country Status (23)
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR081960A1 (es) | 2010-06-22 | 2012-10-31 | Fovea Pharmaceuticals Sa | Compuestos heterociclicos, su preparacion y su aplicacion terapeutica |
| SG11201500125QA (en) | 2012-07-11 | 2015-02-27 | Blueprint Medicines Corp | Inhibitors of the fibroblast growth factor receptor |
| RS63405B1 (sr) | 2013-10-25 | 2022-08-31 | Blueprint Medicines Corp | Inhibitori receptora faktora rasta fibroblasta |
| US9695165B2 (en) | 2014-01-15 | 2017-07-04 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
| KR101715448B1 (ko) * | 2014-07-16 | 2017-03-20 | 주식회사 큐리언트 | 염증성 질환 치료용 화합물 |
| SG11201705192PA (en) | 2014-12-24 | 2017-07-28 | Gilead Sciences Inc | Fused pyrimidine compounds for the treatment of hiv |
| TWI699355B (zh) | 2014-12-24 | 2020-07-21 | 美商基利科學股份有限公司 | 喹唑啉化合物 |
| BR112017013440A2 (pt) | 2014-12-24 | 2018-01-09 | Gilead Sciences, Inc. | compostos de isoquinolina para o tratamento de hiv |
| CN112239459B (zh) * | 2019-07-19 | 2021-11-26 | 中国科学院上海药物研究所 | 稠环嘧啶氨基化合物、其制备方法、药物组合物及应用 |
| CN115916759B (zh) * | 2020-06-19 | 2025-07-15 | 泰州红云制药有限公司 | 取代喹唑啉类化合物、其制备方法、药物组合及应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1235815A1 (en) * | 1999-11-22 | 2002-09-04 | Warner-Lambert Company | Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes |
| MXPA05007503A (es) | 2003-01-17 | 2005-09-21 | Warner Lambert Co | Heterociclicos 2-aminopiridina sustituidos como inhibidores de proliferacion celular. |
| US7691866B2 (en) | 2003-10-16 | 2010-04-06 | Novartis Vaccines And Diagnostics, Inc. | 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines and methods of their use as inhibitors of Raf kinase |
| EP2543376A1 (en) | 2004-04-08 | 2013-01-09 | Targegen, Inc. | Benzotriazine inhibitors of kinases |
| US7652051B2 (en) | 2004-08-25 | 2010-01-26 | Targegen, Inc. | Heterocyclic compounds and methods of use |
| US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| JP2008533166A (ja) | 2005-03-16 | 2008-08-21 | ターゲジェン インコーポレーティッド | ピリミジン化合物および使用法 |
| US7906522B2 (en) * | 2005-04-28 | 2011-03-15 | Kyowa Hakko Kirin Co., Ltd | 2-aminoquinazoline derivatives |
| AU2006254825A1 (en) | 2005-06-08 | 2006-12-14 | Targegen, Inc. | Methods and compositions for the treatment of ocular disorders |
| AR060358A1 (es) * | 2006-04-06 | 2008-06-11 | Novartis Vaccines & Diagnostic | Quinazolinas para la inhibicion de pdk 1 |
| JP2010514693A (ja) * | 2006-12-22 | 2010-05-06 | ノバルティス アーゲー | Ｐｄｋ１阻害のためのキナゾリン |
-
2009
- 2009-12-18 CA CA2748319A patent/CA2748319A1/en not_active Abandoned
- 2009-12-18 CN CN2009801575427A patent/CN102333533A/zh active Pending
- 2009-12-18 WO PCT/EP2009/067494 patent/WO2010076238A1/en not_active Ceased
- 2009-12-18 MA MA34018A patent/MA32968B1/fr unknown
- 2009-12-18 EA EA201101012A patent/EA019110B1/ru not_active IP Right Cessation
- 2009-12-18 MX MX2011007064A patent/MX2011007064A/es active IP Right Grant
- 2009-12-18 PE PE2011001296A patent/PE20120424A1/es not_active Application Discontinuation
- 2009-12-18 EP EP09799340A patent/EP2381943A1/en not_active Withdrawn
- 2009-12-18 AU AU2009334869A patent/AU2009334869A1/en not_active Abandoned
- 2009-12-18 BR BRPI0924067A patent/BRPI0924067A2/pt not_active IP Right Cessation
- 2009-12-18 SG SG2011047339A patent/SG172415A1/en unknown
- 2009-12-18 US US13/142,333 patent/US8389530B2/en not_active Expired - Fee Related
- 2009-12-18 NZ NZ593949A patent/NZ593949A/xx not_active IP Right Cessation
- 2009-12-18 JP JP2011544017A patent/JP2012514020A/ja active Pending
- 2009-12-18 KR KR1020117017495A patent/KR20110120878A/ko not_active Withdrawn
-
2011
- 2011-06-23 IL IL213742A patent/IL213742A0/en unknown
- 2011-06-27 TN TN2011000319A patent/TN2011000319A1/fr unknown
- 2011-06-27 CR CR20110368A patent/CR20110368A/es not_active Application Discontinuation
- 2011-06-28 ZA ZA2011/04777A patent/ZA201104777B/en unknown
- 2011-06-29 CO CO11081323A patent/CO6390105A2/es not_active Application Discontinuation
- 2011-06-29 NI NI201100134A patent/NI201100134A/es unknown
- 2011-06-29 DO DO2011000209A patent/DOP2011000209A/es unknown
- 2011-07-14 EC EC2011011204A patent/ECSP11011204A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2012514020A (ja) | 2012-06-21 |
| US8389530B2 (en) | 2013-03-05 |
| US20120004210A1 (en) | 2012-01-05 |
| SG172415A1 (en) | 2011-07-28 |
| PE20120424A1 (es) | 2012-05-04 |
| DOP2011000209A (es) | 2011-09-30 |
| MA32968B1 (fr) | 2012-01-02 |
| NZ593949A (en) | 2013-08-30 |
| EP2381943A1 (en) | 2011-11-02 |
| ECSP11011204A (es) | 2011-10-31 |
| MX2011007064A (es) | 2012-01-20 |
| BRPI0924067A2 (pt) | 2016-01-26 |
| AU2009334869A2 (en) | 2011-09-29 |
| AU2009334869A1 (en) | 2011-07-14 |
| IL213742A0 (en) | 2011-07-31 |
| CN102333533A (zh) | 2012-01-25 |
| NI201100134A (es) | 2012-03-06 |
| ZA201104777B (en) | 2012-03-28 |
| KR20110120878A (ko) | 2011-11-04 |
| EA201101012A1 (ru) | 2012-01-30 |
| CR20110368A (es) | 2011-12-02 |
| CO6390105A2 (es) | 2012-02-29 |
| WO2010076238A1 (en) | 2010-07-08 |
| TN2011000319A1 (en) | 2012-12-17 |
| EA019110B1 (ru) | 2014-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2748319A1 (en) | Substituted quinazoline compounds of general formula (i) and uses thereof for treating disorders relating to tyrosine kinase dysregulation | |
| CA2917735C (en) | Protein tyrosine kinase modulators and methods of use | |
| CN101619043B (zh) | 喹唑啉衍生物及其医药用途 | |
| ES2461799T3 (es) | Derivados de indolil-piridona que tienen actividad inhibidora de la quinasa de control 1 | |
| ES2638144T3 (es) | Bencilpirazoles sustituidos | |
| CA2551529C (en) | Amide derivative and medicine | |
| JP2012514020A5 (cg-RX-API-DMAC7.html) | ||
| TW434227B (en) | Novel N-benzylindole and benzopyrazole derivatives with anti-asthmatic, anti-allergic, anti-inflammatory and immune modulating effect | |
| CA3160577A1 (en) | Novel aurora kinase inhibitors and use thereof | |
| JP2007523867A5 (cg-RX-API-DMAC7.html) | ||
| ES3040728T3 (en) | Method for introducing deuterated lower alkyl into amine moiety of compound containing secondary amine | |
| WO2009150137A3 (en) | Pyrazine derivatives as epithelial sodium channel blockers | |
| CA3020478A1 (en) | Thiazolopyridine derivatives as gpr119 agonists | |
| ZA200603226B (en) | Amide derivatives | |
| JP2012510502A5 (cg-RX-API-DMAC7.html) | ||
| CA2495577A1 (en) | Novel benzoimidazole derivatives useful as antiproliferative agents | |
| RU2011127451A (ru) | ПРОИЗВОДНЫЕ ТИЕНО[3,2-c]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗ ДЛЯ ПРИМЕНЕНИЯ В ЛЕЧЕНИИ РАКА | |
| NO20074311L (no) | Kinazolinderivat med tyrosinkinase-inhiberendeaktivitet | |
| NZ596025A (en) | [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto | |
| DE602005002475D1 (de) | Verfahren zur vorbereitung von telithromycin | |
| TWI387601B (zh) | 方法及中間物 | |
| SG172229A1 (en) | Thiazolyl-benzimidazoles | |
| HRP20171321T1 (hr) | Postupak za pripremanje spojeva triazola | |
| WO2008104473A3 (en) | Pyrazolopyriidine derivatives and their use as kinase inhibitors | |
| WO2009076602A8 (en) | 5-alkyl/alkenyl-3-cyanopyridines as kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |
Effective date: 20150520 |